Loading
NASDAQHealthcareBiotechnology
Latest quote
$6.20
−$0.31 · -4.76%
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
Previous close
$6.20
−$0.31 · -4.76%
Regular session · ET · Market data may be delayed.
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
Day range
Current $6.20
52-week range
Current $6.20
Regular session · ET · Market data may be delayed.
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
Day range
Current $6.20
52-week range
Current $6.20
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 431.38K USD | 1.3M USD | 1.54M USD |
| Cost of goods sold | — | 255.05K USD | 420.81K USD | 1.22M USD | 1.46M USD |
| Gross profit | — | −255K USD | 10.57K USD | 80.07K USD | 81.85K USD |
| Research and development | 352.88K USD | 1.94M USD | 5.2M USD | 9.22M USD | 10.87M USD |
| Selling, general, and administrative | 1.64M USD | 1.47M USD | 4.42M USD | 7.97M USD | 8.03M USD |
| Operating expenses | 1.82M USD | 3.54M USD | 10.61M USD | 17.25M USD | 19.29M USD |
| Interest income | — | — | — | 146.59K USD | — |
| Interest expense | 95.71K USD | 146.92K USD | 121.15K USD | — | 93.6K USD |
| Depreciation and amortization | — | 255.05K USD | 1.13M USD | 1.21M USD | 1.19M USD |
| Operating income | −1.82M USD | −3.8M USD | −10.6M USD | −17.51M USD | −19.21M USD |
| Net income | −1.36M USD | −4.27M USD | −2.83M USD | −9.8M USD | −25.05M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 20, 2026 | 1:10 | — | — |
Effective Jul 20, 2026
1:10
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
